Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00167921|
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : May 28, 2007
|Condition or disease||Intervention/treatment||Phase|
|Atrophic Vaginitis||Drug: Premarin® Vaginal Cream Drug: Premarin® oral tablets||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multiple-Dose, Comparative Bioavailability Study of Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Postmenopausal Women With Atrophic Vaginitis.|
|Study Start Date :||October 2005|
- To characterize the systemic exposure and bioavailability at steady state of Premarin® Vaginal Cream compared with oral Premarin® tablets in postmenopausal women with atrophic vaginitis.
- To estimate the systemic exposure in postmenopausal women taking a typical regimen.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00167921
|United States, Florida|
|Miami, Florida, United States, 33136|
|United States, Maryland|
|Baltimore, Maryland, United States, 21225|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|